Ogenix to Showcase the EpiFLO for Treatment of Diabetic Foot and Leg Ulcers at Workers' Compensation Conference

Ogenix, a medical technology company that develops and markets a breakthrough oxygen-generating device used in the treatment of diabetic foot and leg ulcers and other chronic and acute wounds, announced today the company's participation in the 63rd Annual Workers' Compensation Educational Conference and 20th Annual Safety and Health Conference in Orlando on August 17-20th, 2008.

Sample devices will be presented and demonstrations will be conducted at Booth # 338 throughout the conference.

The EpiFLO®, a 3 ounce portable device, has demonstrated the ability to effectively heal wounds by delivering a sustained stream of oxygen directly to the wound bed 24/7, resulting in closure of many wounds that have previously failed standard wound care and other therapies.

According to Neil Saffer, Managing Director of Ogenix, "Oxygen therapy continues to gain recognition within the medical community as a safe and highly effective treatment and it is fast becoming part of the standard treatments of many types of wounds. Our device, the EpiFLO®, has been responsible for the closure of many wounds, including many that previously resulted in scheduled amputations. Not only is it the treatment of choice for many wound care professionals, it is also highly favored by payers for its reduced treatment time and cost reduction."

The Ogenix exhibit will enable health care professionals to view the device and discuss its role in wound care treatment with company executives.

About Ogenix

Ogenix is a medical device developer that manufactures and markets the EpiFLO®, a palm sized medical device used in sustained oxygen delivery for chronic wound treatment. For additional information, please refer to their website at www.ogenix.com.